Gunilla Lundmark is CEO of Pharmanest AB, and has more than 20 years of experience working in top management positions in the international life science industry, including Pharmacia and Q-Med, where she previously was Vice President of Q-Med AB. She has international experience of marketing and sales and excellent understanding of business after managing different functions in top management and product development.
Andy Carter, Ph. D., is founder and CEO of Accent Biomedical, a provider of Innovation Services and consultancy to the Biomaterials and Medical Device industry. Dr. Carter has more than 25 years of experience from R&D within the orthopedics industry, including Smith & Nephew, a leading orthopedic implants company, where he was Group Director of R&D.
Maria Fors is CEO of Accelerator Nordic AB. She has a background from both Strategic Marketing and Product Marketing at GE Healthcare where she most recently was Marketing Manager.
"The positive clinical results that we now have in place since the beginning of the year have further improved our possibilities to enter into partnering discussions regarding AddBIO's product. With the new board of directors, we have broad experience and knowledge of commercializing new, innovative products, and are therefore well equipped to be able to take Zolidd to the market successfully", says Andreas Bunge, Chairman of the Board, AddBIO AB.
AddBIO AB has developed Zolidd®, a proprietary bioactive nanolayer for orthopedic and dental implants that releases bisphosphonate, a bone strengthening drug. In February, positive results from a randomized clinical trial, conducted at Linköping University Hospital in Sweden, were presented that show that dental implants with a bisphosphonate nanolayer have improved stability.
For additional information, please contact Andreas Bunge, Chairman of the Board, AddBIO AB, +46 70 824 25 25, or Maria Fors, CEO Accelerator Nordic AB, +46 76 119 1983.
Accelerator Nordic AB is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator's subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, www.acceleratorab.se